Trial Profile
A phase II study evaluating the effect of the addition of lenalidomide to R-CHOP for patients with newly diagnosed MYC positive DLBCL and BCL-U
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Apr 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms HOVON 130 NHL
- 07 Apr 2022 This trial has been completed in Belgium (Date of the global end of the trial : 31-Jan-2022), according to European Clinical Trials Database record.
- 14 Dec 2021 Results (N 323) HOVON-84, HOVON-130, and PETAL trials investigating ability to predict outcome in DLBCL can be improved by combining different clinical, radiomics and genetic features presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 17 Jun 2021 Results of HOVON-130 (n=80 MYC+ DLBCL patients), and HOVON-84 (n=126 MYC- DLBCL patients) study assessing 18F-FDG PET/CT response in DLBCL patients with MYC rearrangements compared to the response patterns of DLBCL patients without MYC rearrangements, presented at the 26th Congress of the European Haematology Association.